|
Patents,
policies and more
Dr Swati Piramal, Director-Strategic Alliances, Nicholas Piramal
voices her opinions on the company and its alliances, government
policies and R&D; in conversation with Katya Naidu.
Upfront
Glenmark
acquires Medicamenta
Glenmark Holdings SA concluded a deal to acquire a majority
shareholding of more than 90 percent stake of the company
Medicamenta, giving Glenmark its first commercial foothold
into the strategically important market of Europe.
Serum
launches HIB vaccine
Serum Institute has announced the launch of its indigenously
developed HIB vaccine.
Wockhardt
gets two FDA approvals
Wockhardt has announced USFDA approval for marketing Furosemide
and Ketorolac injections in the US market.
GSK
opens a lab in Singapore
GlaxoSmithKline opened its new medicinal chemistry laboratory
at its R&D facility in Singapore's biomedical research
hub, Biopolis.
Strides
receives approval for Efavirenz
Strides Arcolab has received tentative approval from the USFDA
for Efavirenz tablets under the expedited review provisions
of the President's Emergency Plan for Aids Relief (PEPFAR)
programme.
In
Spanish pursuits
Elder Pharmaceuticals has recently entered into an alliance
with Laboratorios Farmaceuticos Rovi, SA of Spain to market
advanced heparins (anti-thrombotics) in India. Alok Saxena,
Director International, Elder Pharmaceuticals speaks on the
development.
GVK
grows in the CRO space
GVK BIO has collaborated with INC Research to form INC GVK
BIO Private Limited, which would establish a resource capability
to offer Phase I-IV clinical development programmes in India
for INC's global clients. Shabbir Rangwala, the Director of
Clinical Research and Data Management of GVK Biosciences speaks
on the development
Court
reserves order in Novartis patent case
A court in India reserved its verdict on a challenge by Novartis
AG against an Indian law that blocks patenting of minor improvements
in known molecules.
Emerging
opportunities in CRAMS
The Contract Research and Manufacturing Services (CRAMS) industry
can be estimated to be churning revenues of $850 million annually.
Upcoming
Events
BioOne
sets up cell culture facility
Lonza group and BioOne Capital have set up their commercial
mammalian cell culture manufacturing facility at Tuas Biomedical
Park.
Investco
picks up 14.9 percent stake in Granules
Granules India has announced the issue of 22.11 lakh equity
shares of Rs 10 each, fully paid-up at Rs 105.50
per share (including premium), to ISP Investco on a preferential
basis, subject to the approval of the shareholders of the
company at an Extraordinary General Meeting.
|
